Novo Holdings is pleased to announce the appointment of Dr Donald A. Deieso, CEO and Executive Chairman of WCG, to the Novo Advisory Group. The Novo Advisory Group (NAG) is an expert panel that supports Novo Holdings in analysing and monitoring its larger life science investments.

“We are very pleased to welcome Donald Deieso to the NAG. Don has devoted most of his career to healthcare and serving the patient, particularly by improving the clinical trial experience. This, combined with his significant leadership experience from publicly traded and privately-held companies, makes Don an ideal member of the NAG and I am truly delighted at the opportunity to continue our strong working relationship,” said Kasim Kutay, CEO of Novo Holdings.

Dr Deieso founded WCG, a Novo Holdings Investment Portfolio company, in 2012 and has served as Executive Chairman since its founding. In 2013, he assumed the additional role of CEO at WCG. Prior to that, Dr Deieso served as an operating partner and co-head of the Healthcare Group at Arsenal Capital Partners. Additionally, he has held CEO positions at a number of privately held companies in the healthcare, life sciences, technology, and engineering industries and has held senior positions in federal and state regulatory agencies.

Donald Deieso said: “I am delighted to join this extraordinary group of industry leaders who are committed to improving global health through collaborative investments in the exciting advances in clinical science and technology. It is a privilege to contribute to the mission of Novo Holdings at a time of great promise for mankind”.

About Donald A. Deieso

American citizen

Career
2013 – CEO, WCG
2012 – Executive Chair and Founder, WCG
2011-2019: Operating Partner & Co-head, Arsenal Capital Partners

Current board positions
Currently, Dr Deieso serves on the board of WCG Clinical, and Inspire.

Education
MS and PhD from Rutgers University and BS in mechanical engineering from Manhattan College.